StockNews.com started coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Free Report) (TSE:AEZ) in a research note issued to investors on Monday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Trading Up 0.5 %
NASDAQ AEZS opened at $2.89 on Monday. Aeterna Zentaris has a 1-year low of $3.96 and a 1-year high of $12.00. The company has a market capitalization of $5.18 million, a PE ratio of -0.19 and a beta of 1.55. The firm’s fifty day simple moving average is $2.96 and its 200-day simple moving average is $3.99.
Aeterna Zentaris Company Profile
Further Reading
- Five stocks we like better than Aeterna Zentaris
- What Does a Stock Split Mean?
- Sizing Up a New Opportunity for NVIDIA Investors
- How to trade using analyst ratings
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- Quiet Period Expirations Explained
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.